Dare Bioscience (DARE) Non Operating Interest Expenses (2013 - 2025)
Dare Bioscience's (DARE) quarterly Non Operating Interest Expenses came in at $134050.0 in Q1 2025, down 35.9% on a YoY basis from $209138.0 in Q1 2024, and down 35.9% quarter-over-quarter from $209138.0 in Q1 2024.
Powered by 
Analysis
Dare Bioscience (DARE) Non Operating Interest Expenses (2013 - 2025) Analysis & Trends
Dare Bioscience (DARE) has reported Non Operating Interest Expenses for 7 consecutive years, with $134050.0 the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Non Operating Interest Expenses fell 35.9% year-over-year to $134050.0; the trailing twelve-month figure through Mar 2025 stood at $1.1 million (down 22.07% YoY), and the FY2017 full-year result was $322629.0, up 666.41% from the prior year.
- Non Operating Interest Expenses slipped to $134050.0 in Q1 2025 per DARE's latest filing, from $209138.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $209138.0 in Q1 2024 and bottomed at $134050.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Dare Bioscience | 10.67 Mn | -1.95 Mn | -132,343.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 134,050.00 |
| Mar 31, 2024 | 209,138.00 |
| Mar 31, 2017 | 797,000.00 |
| Dec 31, 2016 | 457,000.00 |
| Sep 30, 2016 | 521,000.00 |
| Jun 30, 2016 | 597,000.00 |
| Mar 31, 2016 | 670,000.00 |
| Dec 31, 2015 | 689,000.00 |
| Sep 30, 2015 | 509,000.00 |
| Jun 30, 2015 | 513,000.00 |
| Mar 31, 2015 | 721,000.00 |
| Dec 31, 2014 | 163,000.00 |
| Sep 30, 2014 | 191,000.00 |
| Jun 30, 2014 | 268,000.00 |
| Mar 31, 2014 | 461,000.00 |
| Dec 31, 2013 | 430,000.00 |
| Sep 30, 2013 | 378,000.00 |
| Jun 30, 2013 | 326,000.00 |
| Mar 31, 2013 | 353,000.00 |